PF-04929113, also known as SNX-5422; is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5542 is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation.
HSP (HSP90) inhibitor Related Prodcuts:
Tanespimycin; Luminespib; Alvespimycin; Ganetespib; BIIB021; Onalespib; NVP-BEP800; SNX-2112; KW-2478; XL888; Zelavespib (PU-H71); KRIBB11; VER-50589; Triptolide; NVP-HSP990; Dimethylenastron; Geldanamycin